Mark Tyson/X
May 28, 2025, 06:14
Mark Tyson Comments on Real-World Outcomes of Intravesical Gemcitabine in BCG-Unresponsive Bladder Cancer
Mark Tyson, Associate Professor of Urology at Mayo Clinic in Arizona, posted on X:
“Analysis of intravesical gem at MSK: 12mo HGRFS was 52% in BCG-u bladder cancer.
Off-trial patients did better (66%) vs. on-trial (25%)—highlighting selection in trials vs realworld. Gem/doce’s “standard” status needs prospective validation IMO. Need RCT. Love this.”
More posts featuring bladder cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:58
May 29, 2025, 17:45
May 29, 2025, 17:39
May 29, 2025, 17:28